HBV genotypes and drug resistance mutations in antiretroviral treatment-naïve and treatment-experienced HBV-HIV co-infected patients
Identifieur interne : 000385 ( Pmc/Corpus ); précédent : 000384; suivant : 000386HBV genotypes and drug resistance mutations in antiretroviral treatment-naïve and treatment-experienced HBV-HIV co-infected patients
Auteurs : Timothy N. A. Archampong ; Ceejay L. Boyce ; Margaret Lartey ; Kwamena W. Sagoe ; Adjoa Obo-Akwa ; Ernest Kenu ; Jason T. Blackard ; Awewura KwaraSource :
- Antiviral therapy [ 1359-6535 ] ; 2016.
Abstract
The presence of hepatitis B virus (HBV) resistance mutations upon initiation or during antiretroviral therapy (ART) in HIV co-infected patients is an important determinant of treatment response. The main objective of the study was to determine the prevalence of HBV resistance mutations in antiretroviral treatment-naïve and treatment-experienced HBV-HIV co-infected Ghanaian patients with detectable HBV viremia.
HBV-HIV co-infected patients who were ART-naïve or had received at least 9 months of lamivudine (3TC)-containing ART were enrolled in a cross-sectional study. Demographic and clinical data were collected and HBV DNA quantified. Partial HBV sequences were amplified by PCR and sequenced bi-directionally to obtain a 2.1-2.2 kb fragment for phylogenetic analysis of HBV genotypes and evaluation of drug resistance mutations.
Of the 100 HBV-HIV co-infected study patients, 75 were successfully PCR-amplified, and 63 were successfully sequenced. Of these 63 patients, 27 (42.9%) were ART-experienced, and 58 (92.1%) had HBV genotype E. No resistance mutations were observed in the 36 ART-naïve patients, while 21 (77.8%) of 27 treatment-experienced patients had resistance mutations. All patients with resistance mutations had no tenofovir (TDF) in their regimens, and 80% of them had HIV RNA < 40 copies/mL. The 3TC resistance mutations rtL180M and rtM204V were observed in 10 (47.6%) of the 21 patients, while 5 patients (23.8%) had rtV173, rtL80I, and rtM204V mutations.
A high proportion of HBV-HIV co-infected patients with detectable viremia on 3TC-containing ART had resistance mutations despite good ART adherence as determined by HIV RNA suppression. This study emphasizes the need for dual therapy as part of a fully suppressive ART in all HBV-HIV co-infected patients in Ghana.
Url:
DOI: 10.3851/IMP3055
PubMed: 27167598
PubMed Central: 5106338
Links to Exploration step
PMC:5106338Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">HBV genotypes and drug resistance mutations in antiretroviral treatment-naïve and treatment-experienced HBV-HIV co-infected patients</title><author><name sortKey="Archampong, Timothy N A" sort="Archampong, Timothy N A" uniqKey="Archampong T" first="Timothy N. A." last="Archampong">Timothy N. A. Archampong</name><affiliation><nlm:aff id="A1">Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Korle-Bu Teaching Hospital, Accra, Ghana</nlm:aff></affiliation></author><author><name sortKey="Boyce, Ceejay L" sort="Boyce, Ceejay L" uniqKey="Boyce C" first="Ceejay L." last="Boyce">Ceejay L. Boyce</name><affiliation><nlm:aff id="A3">Division of Digestive Disease, University of Cincinnati College of Medicine, Cincinnati, OH, USA</nlm:aff></affiliation></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation><nlm:aff id="A1">Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Korle-Bu Teaching Hospital, Accra, Ghana</nlm:aff></affiliation></author><author><name sortKey="Sagoe, Kwamena W" sort="Sagoe, Kwamena W" uniqKey="Sagoe K" first="Kwamena W." last="Sagoe">Kwamena W. Sagoe</name><affiliation><nlm:aff id="A4">Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, Accra, Ghana</nlm:aff></affiliation></author><author><name sortKey="Obo Akwa, Adjoa" sort="Obo Akwa, Adjoa" uniqKey="Obo Akwa A" first="Adjoa" last="Obo-Akwa">Adjoa Obo-Akwa</name><affiliation><nlm:aff id="A1">Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana</nlm:aff></affiliation></author><author><name sortKey="Kenu, Ernest" sort="Kenu, Ernest" uniqKey="Kenu E" first="Ernest" last="Kenu">Ernest Kenu</name><affiliation><nlm:aff id="A2">Korle-Bu Teaching Hospital, Accra, Ghana</nlm:aff></affiliation><affiliation><nlm:aff id="A5">School of Public Health, College of Health Sciences, University of Ghana</nlm:aff></affiliation></author><author><name sortKey="Blackard, Jason T" sort="Blackard, Jason T" uniqKey="Blackard J" first="Jason T." last="Blackard">Jason T. Blackard</name><affiliation><nlm:aff id="A3">Division of Digestive Disease, University of Cincinnati College of Medicine, Cincinnati, OH, USA</nlm:aff></affiliation></author><author><name sortKey="Kwara, Awewura" sort="Kwara, Awewura" uniqKey="Kwara A" first="Awewura" last="Kwara">Awewura Kwara</name><affiliation><nlm:aff id="A6">Warren Alpert Medical School of Brown University, Providence, RI, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A7">The Miriam Hospital, Providence, RI, USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27167598</idno><idno type="pmc">5106338</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106338</idno><idno type="RBID">PMC:5106338</idno><idno type="doi">10.3851/IMP3055</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">000385</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000385</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">HBV genotypes and drug resistance mutations in antiretroviral treatment-naïve and treatment-experienced HBV-HIV co-infected patients</title><author><name sortKey="Archampong, Timothy N A" sort="Archampong, Timothy N A" uniqKey="Archampong T" first="Timothy N. A." last="Archampong">Timothy N. A. Archampong</name><affiliation><nlm:aff id="A1">Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Korle-Bu Teaching Hospital, Accra, Ghana</nlm:aff></affiliation></author><author><name sortKey="Boyce, Ceejay L" sort="Boyce, Ceejay L" uniqKey="Boyce C" first="Ceejay L." last="Boyce">Ceejay L. Boyce</name><affiliation><nlm:aff id="A3">Division of Digestive Disease, University of Cincinnati College of Medicine, Cincinnati, OH, USA</nlm:aff></affiliation></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation><nlm:aff id="A1">Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Korle-Bu Teaching Hospital, Accra, Ghana</nlm:aff></affiliation></author><author><name sortKey="Sagoe, Kwamena W" sort="Sagoe, Kwamena W" uniqKey="Sagoe K" first="Kwamena W." last="Sagoe">Kwamena W. Sagoe</name><affiliation><nlm:aff id="A4">Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, Accra, Ghana</nlm:aff></affiliation></author><author><name sortKey="Obo Akwa, Adjoa" sort="Obo Akwa, Adjoa" uniqKey="Obo Akwa A" first="Adjoa" last="Obo-Akwa">Adjoa Obo-Akwa</name><affiliation><nlm:aff id="A1">Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana</nlm:aff></affiliation></author><author><name sortKey="Kenu, Ernest" sort="Kenu, Ernest" uniqKey="Kenu E" first="Ernest" last="Kenu">Ernest Kenu</name><affiliation><nlm:aff id="A2">Korle-Bu Teaching Hospital, Accra, Ghana</nlm:aff></affiliation><affiliation><nlm:aff id="A5">School of Public Health, College of Health Sciences, University of Ghana</nlm:aff></affiliation></author><author><name sortKey="Blackard, Jason T" sort="Blackard, Jason T" uniqKey="Blackard J" first="Jason T." last="Blackard">Jason T. Blackard</name><affiliation><nlm:aff id="A3">Division of Digestive Disease, University of Cincinnati College of Medicine, Cincinnati, OH, USA</nlm:aff></affiliation></author><author><name sortKey="Kwara, Awewura" sort="Kwara, Awewura" uniqKey="Kwara A" first="Awewura" last="Kwara">Awewura Kwara</name><affiliation><nlm:aff id="A6">Warren Alpert Medical School of Brown University, Providence, RI, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A7">The Miriam Hospital, Providence, RI, USA</nlm:aff></affiliation></author></analytic><series><title level="j">Antiviral therapy</title><idno type="ISSN">1359-6535</idno><idno type="eISSN">2040-2058</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title><p id="P1">The presence of hepatitis B virus (HBV) resistance mutations upon initiation or during antiretroviral therapy (ART) in HIV co-infected patients is an important determinant of treatment response. The main objective of the study was to determine the prevalence of HBV resistance mutations in antiretroviral treatment-naïve and treatment-experienced HBV-HIV co-infected Ghanaian patients with detectable HBV viremia.</p></sec><sec id="S2"><title>Methods</title><p id="P2">HBV-HIV co-infected patients who were ART-naïve or had received at least 9 months of lamivudine (3TC)-containing ART were enrolled in a cross-sectional study. Demographic and clinical data were collected and HBV DNA quantified. Partial HBV sequences were amplified by PCR and sequenced bi-directionally to obtain a 2.1-2.2 kb fragment for phylogenetic analysis of HBV genotypes and evaluation of drug resistance mutations.</p></sec><sec id="S3"><title>Results</title><p id="P3">Of the 100 HBV-HIV co-infected study patients, 75 were successfully PCR-amplified, and 63 were successfully sequenced. Of these 63 patients, 27 (42.9%) were ART-experienced, and 58 (92.1%) had HBV genotype E. No resistance mutations were observed in the 36 ART-naïve patients, while 21 (77.8%) of 27 treatment-experienced patients had resistance mutations. All patients with resistance mutations had no tenofovir (TDF) in their regimens, and 80% of them had HIV RNA < 40 copies/mL. The 3TC resistance mutations rtL180M and rtM204V were observed in 10 (47.6%) of the 21 patients, while 5 patients (23.8%) had rtV173, rtL80I, and rtM204V mutations.</p></sec><sec id="S4"><title>Discussion</title><p id="P4">A high proportion of HBV-HIV co-infected patients with detectable viremia on 3TC-containing ART had resistance mutations despite good ART adherence as determined by HIV RNA suppression. This study emphasizes the need for dual therapy as part of a fully suppressive ART in all HBV-HIV co-infected patients in Ghana.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">9815705</journal-id><journal-id journal-id-type="pubmed-jr-id">21447</journal-id><journal-id journal-id-type="nlm-ta">Antivir Ther</journal-id><journal-id journal-id-type="iso-abbrev">Antivir. Ther. (Lond.)</journal-id><journal-title-group><journal-title>Antiviral therapy</journal-title></journal-title-group><issn pub-type="ppub">1359-6535</issn><issn pub-type="epub">2040-2058</issn></journal-meta><article-meta><article-id pub-id-type="pmid">27167598</article-id><article-id pub-id-type="pmc">5106338</article-id><article-id pub-id-type="doi">10.3851/IMP3055</article-id><article-id pub-id-type="manuscript">NIHMS796471</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>HBV genotypes and drug resistance mutations in antiretroviral treatment-naïve and treatment-experienced HBV-HIV co-infected patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Archampong</surname><given-names>Timothy N. A.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref rid="FN2" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Boyce</surname><given-names>Ceejay L.</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref rid="FN2" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Lartey</surname><given-names>Margaret</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sagoe</surname><given-names>Kwamena W.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Obo-Akwa</surname><given-names>Adjoa</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kenu</surname><given-names>Ernest</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Blackard</surname><given-names>Jason T.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kwara</surname><given-names>Awewura</given-names></name><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A7">7</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana</aff><aff id="A2"><label>2</label>Korle-Bu Teaching Hospital, Accra, Ghana</aff><aff id="A3"><label>3</label>Division of Digestive Disease, University of Cincinnati College of Medicine, Cincinnati, OH, USA</aff><aff id="A4"><label>4</label>Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, Accra, Ghana</aff><aff id="A5"><label>5</label>School of Public Health, College of Health Sciences, University of Ghana</aff><aff id="A6"><label>6</label>Warren Alpert Medical School of Brown University, Providence, RI, USA</aff><aff id="A7"><label>7</label>The Miriam Hospital, Providence, RI, USA</aff><author-notes><corresp id="FN1">Corresponding author: Timothy N. A. Archampong; Lecturer, Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana; PO Box 4236, Korle-Bu, Accra, Ghana, <email>tnaa@doctors.net.uk</email>; Tel: 00233-203039841</corresp><fn id="FN2" fn-type="equal"><label>*</label><p>These authors contributed equally to this manuscript</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>22</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>11</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>3</month><year>2017</year></pub-date><volume>22</volume><issue>1</issue><fpage>13</fpage><lpage>20</lpage><pmc-comment>elocation-id from pubmed: 10.3851/IMP3055</pmc-comment>
<abstract><sec id="S1"><title>Background</title><p id="P1">The presence of hepatitis B virus (HBV) resistance mutations upon initiation or during antiretroviral therapy (ART) in HIV co-infected patients is an important determinant of treatment response. The main objective of the study was to determine the prevalence of HBV resistance mutations in antiretroviral treatment-naïve and treatment-experienced HBV-HIV co-infected Ghanaian patients with detectable HBV viremia.</p></sec><sec id="S2"><title>Methods</title><p id="P2">HBV-HIV co-infected patients who were ART-naïve or had received at least 9 months of lamivudine (3TC)-containing ART were enrolled in a cross-sectional study. Demographic and clinical data were collected and HBV DNA quantified. Partial HBV sequences were amplified by PCR and sequenced bi-directionally to obtain a 2.1-2.2 kb fragment for phylogenetic analysis of HBV genotypes and evaluation of drug resistance mutations.</p></sec><sec id="S3"><title>Results</title><p id="P3">Of the 100 HBV-HIV co-infected study patients, 75 were successfully PCR-amplified, and 63 were successfully sequenced. Of these 63 patients, 27 (42.9%) were ART-experienced, and 58 (92.1%) had HBV genotype E. No resistance mutations were observed in the 36 ART-naïve patients, while 21 (77.8%) of 27 treatment-experienced patients had resistance mutations. All patients with resistance mutations had no tenofovir (TDF) in their regimens, and 80% of them had HIV RNA < 40 copies/mL. The 3TC resistance mutations rtL180M and rtM204V were observed in 10 (47.6%) of the 21 patients, while 5 patients (23.8%) had rtV173, rtL80I, and rtM204V mutations.</p></sec><sec id="S4"><title>Discussion</title><p id="P4">A high proportion of HBV-HIV co-infected patients with detectable viremia on 3TC-containing ART had resistance mutations despite good ART adherence as determined by HIV RNA suppression. This study emphasizes the need for dual therapy as part of a fully suppressive ART in all HBV-HIV co-infected patients in Ghana.</p></sec></abstract><kwd-group><kwd>Hepatitis B virus</kwd><kwd>HIV</kwd><kwd>co-infection</kwd><kwd>Ghana</kwd><kwd>Africa</kwd><kwd>genotype</kwd><kwd>drug resistance</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000385 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000385 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:5106338
|texte= HBV genotypes and drug resistance mutations in antiretroviral treatment-naïve and treatment-experienced HBV-HIV co-infected patients
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:27167598" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |